

Besivance

PRICE	N/A
COMPANY	Bausch & Lomb
PHONE	(877) 442-6925
WEB	www.besivance.com
KEY FEATURES	
<ul style="list-style-type: none"> • First fluoroquinolone developed specifically for ophthalmic use • Indicated for the treatment of bacterial conjunctivitis in patients 1 year and older • Associated with a low incidence of adverse effects 	

The FDA has approved Besivance (besifloxacin ophthalmic suspension 0.6%; Bausch & Lomb, Rochester, NY) for the treatment of bacterial conjunctivitis.

A randomized, double-masked, multi-center clinical trial showed that a higher percentage of patients who used Besivance versus the vehicle t.i.d. had a complete resolution of conjunctivitis on day 5 (45% vs 33%). Besivance was associated with a low incidence of adverse events, with fewer than 3% of patients reporting hyperemia, blurred vision, headache, ocular pain, irritation, and itching.



Visco Shield Topical

PRICE	N/A
COMPANY	OASIS Medical, Inc.
PHONE	(909) 305-5400
WEB	www.oasismedical.com
KEY FEATURES	
<ul style="list-style-type: none"> • Designed to adhere to the corneal surface during ophthalmic surgery • Controlled rate of evaporation reportedly eliminates the need for repeated irrigation of the corneal surface • Six 1.5-mL sterile syringes per box 	

Visco Shield Topical (OASIS Medical, Glendora, CA) is a topical sterile ophthalmic viscosurgical device designed to protect the anterior surface of the cornea during ophthalmic surgery. The viscoelastic creates a thin, optically neutral clear film that reportedly adheres to the eye without changing the anterior corneal curvature. According to the company, the protective film remains on the eye for up to 20 minutes, thus reducing the need for repeated irrigation during the surgical procedure. ■

